Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 3 | 2019 | 14 | 1.220 |
Why?
|
| Infant, Newborn | 16 | 2024 | 1375 | 0.790 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2024 | 158 | 0.740 |
Why?
|
| Staphylococcal Infections | 4 | 2023 | 130 | 0.650 |
Why?
|
| Skull Fractures | 1 | 2020 | 22 | 0.640 |
Why?
|
| Laser Therapy | 1 | 2018 | 42 | 0.550 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 142 | 0.540 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2021 | 66 | 0.480 |
Why?
|
| Cross Infection | 3 | 2021 | 167 | 0.460 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2021 | 83 | 0.450 |
Why?
|
| Infant, Premature | 5 | 2023 | 184 | 0.450 |
Why?
|
| Staphylococcus aureus | 2 | 2023 | 179 | 0.340 |
Why?
|
| Massage | 3 | 2012 | 8 | 0.280 |
Why?
|
| Hypothermia, Induced | 2 | 2015 | 40 | 0.230 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2025 | 32 | 0.230 |
Why?
|
| Gestational Age | 3 | 2018 | 191 | 0.210 |
Why?
|
| Cefazolin | 1 | 2023 | 9 | 0.210 |
Why?
|
| Carbapenems | 1 | 2023 | 7 | 0.210 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2025 | 351 | 0.200 |
Why?
|
| Behavior, Animal | 1 | 2025 | 234 | 0.200 |
Why?
|
| Psychotropic Drugs | 1 | 2024 | 82 | 0.200 |
Why?
|
| Seizures | 1 | 2024 | 143 | 0.190 |
Why?
|
| Bacteremia | 1 | 2023 | 94 | 0.190 |
Why?
|
| Infant, Premature, Diseases | 1 | 2003 | 47 | 0.190 |
Why?
|
| Birth Weight | 2 | 2018 | 85 | 0.180 |
Why?
|
| Infant | 3 | 2021 | 1664 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2012 | 85 | 0.170 |
Why?
|
| Humans | 16 | 2024 | 64243 | 0.170 |
Why?
|
| Retrospective Studies | 4 | 2021 | 6726 | 0.160 |
Why?
|
| Neonatology | 1 | 2020 | 4 | 0.160 |
Why?
|
| Lung | 1 | 2025 | 964 | 0.160 |
Why?
|
| Skull | 1 | 2020 | 50 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 800 | 0.160 |
Why?
|
| Ultrasonography | 2 | 2020 | 486 | 0.160 |
Why?
|
| Hyperoxia | 1 | 2019 | 17 | 0.150 |
Why?
|
| Hypothermia | 2 | 2015 | 17 | 0.150 |
Why?
|
| Accidental Falls | 1 | 2020 | 125 | 0.150 |
Why?
|
| Darbepoetin alfa | 2 | 2015 | 5 | 0.150 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2018 | 6 | 0.140 |
Why?
|
| Checklist | 1 | 2019 | 75 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 132 | 0.140 |
Why?
|
| Risk | 1 | 2019 | 379 | 0.140 |
Why?
|
| Pregnancy | 2 | 2024 | 2370 | 0.140 |
Why?
|
| Erythropoietin | 3 | 2015 | 40 | 0.140 |
Why?
|
| Infant, Extremely Premature | 1 | 2018 | 38 | 0.140 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 2238 | 0.140 |
Why?
|
| Anthropometry | 2 | 2015 | 85 | 0.140 |
Why?
|
| Oxygen | 1 | 2019 | 321 | 0.130 |
Why?
|
| Male | 10 | 2024 | 30295 | 0.130 |
Why?
|
| Female | 9 | 2025 | 33351 | 0.120 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2015 | 9 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 389 | 0.120 |
Why?
|
| Hematinics | 1 | 2015 | 11 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2019 | 3315 | 0.120 |
Why?
|
| Docosahexaenoic Acids | 1 | 2015 | 32 | 0.120 |
Why?
|
| Brain Edema | 1 | 2015 | 31 | 0.110 |
Why?
|
| Arm | 1 | 2015 | 46 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 74 | 0.110 |
Why?
|
| Logistic Models | 1 | 2018 | 1270 | 0.110 |
Why?
|
| Adiposity | 1 | 2015 | 83 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 455 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2015 | 78 | 0.110 |
Why?
|
| White Matter | 1 | 2015 | 123 | 0.110 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2015 | 99 | 0.100 |
Why?
|
| Body Fat Distribution | 1 | 2012 | 14 | 0.100 |
Why?
|
| Kinesthesis | 1 | 2012 | 5 | 0.100 |
Why?
|
| Adiponectin | 1 | 2012 | 37 | 0.090 |
Why?
|
| Osteocalcin | 1 | 2012 | 47 | 0.090 |
Why?
|
| Acoustics | 1 | 2012 | 11 | 0.090 |
Why?
|
| Autonomic Nervous System | 1 | 2012 | 36 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1669 | 0.090 |
Why?
|
| Leptin | 1 | 2012 | 87 | 0.090 |
Why?
|
| Tibia | 1 | 2012 | 70 | 0.090 |
Why?
|
| Risk Factors | 2 | 2021 | 5339 | 0.090 |
Why?
|
| Weight Gain | 1 | 2012 | 168 | 0.090 |
Why?
|
| Cognitive Dysfunction | 1 | 2015 | 344 | 0.080 |
Why?
|
| Heart Rate | 1 | 2012 | 327 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2010 | 142 | 0.070 |
Why?
|
| Hippocampus | 1 | 2010 | 278 | 0.070 |
Why?
|
| Sheep | 1 | 2025 | 182 | 0.060 |
Why?
|
| Animals, Newborn | 1 | 2025 | 245 | 0.060 |
Why?
|
| Maze Learning | 2 | 2015 | 55 | 0.050 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2003 | 18 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 58 | 0.050 |
Why?
|
| Body Weight | 2 | 2015 | 379 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 467 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2015 | 744 | 0.050 |
Why?
|
| Mupirocin | 1 | 2021 | 3 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2015 | 625 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2003 | 183 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 84 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 116 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 458 | 0.040 |
Why?
|
| Rats | 2 | 2015 | 2005 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 207 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 1272 | 0.040 |
Why?
|
| Prognosis | 1 | 2003 | 1769 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1130 | 0.030 |
Why?
|
| Animals | 3 | 2025 | 20962 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 606 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 65 | 0.030 |
Why?
|
| Plethysmography | 1 | 2015 | 12 | 0.030 |
Why?
|
| Term Birth | 1 | 2015 | 7 | 0.030 |
Why?
|
| Body Size | 1 | 2015 | 23 | 0.030 |
Why?
|
| Intensive Care, Neonatal | 1 | 2015 | 10 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 728 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 149 | 0.030 |
Why?
|
| Body Composition | 1 | 2015 | 153 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 299 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 869 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2023 | 5691 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2015 | 296 | 0.020 |
Why?
|
| Arousal | 1 | 2012 | 43 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 101 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 331 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2015 | 507 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 48 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 544 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 587 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 979 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 267 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2012 | 554 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2604 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 309 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 17117 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2737 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7923 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2217 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 4776 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1551 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 6304 | 0.010 |
Why?
|